Welcome to Flow Pharma Inc.

Page Loading...

Menu
blob-1
blob-2
Our Biomedicines

FLOVID-20

FLOVID-20 should keep COVID-19 patients healthy and out of the hospital

Targeted T-cell Immunotherapy, designed for COVID-19 patients to keep them out of the hospital. Inhalational delivery of a preventative and therapeutic immuno-stimulatory biomedicine targeting nucleocapsid epitopes on SARS-CoV-2.


Overview

  • Under Development, FDA Approval Required.
  • In Spring 2020, FLOVID-20 non-human primate studies were performed at the United States National Laboratory, University of Texas Medical Branch, Galveston
  • Treated primates resisted infection and control primates became seriously ill with COVID.
  • Data analysis and a scientific manuscript will be presented in early Fall 2020.

Current Status

  • PRE-CLINICAL FEASIBILITY
  • MANUFACTURING FOR CLINICAL TESTING
  • PHASE I/II CLINICAL TESTING

Treated primates resisted infection and control primates contracted serious pneumonia.

How Does Our Therapy Work?


What is COVID-19 and SARS-CoV-2?

Novel Coronavirus SARS-CoV-2

COVID-19 is the disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. The virus shown was isolated from a patient in the U.S. Image captured and colorized at NIAID’s Rocky Mountain Laboratories (RML) in Hamilton, Montana. Credit: NIAID

Read More.


Want to learn more about the science behind the solution?

View Resources